Skip to main content

HomeResearchVilon

Educational research tools — not medical advice.

CategoryLongevity
SafetyLow Risk
RegulatoryNot Evaluated
StatusResearch Only

Vilon

Lys-Glu · Khavinson immune dipeptide

CategoryLongevity
Half-lifeUnknown
Routesubcutaneous, intramuscular
RiskLow Risk
Providers2 listed#10 in Longevity

In brief

Vilon is a synthetic dipeptide (Lys-Glu, KE) classified as a Khavinson-class bioregulator originally derived from thymic tissue, proposed to modulate immune function in aging subjects by providing minimal thymic…

Low Risk2 providers listed

About Vilon

Synthetic dipeptide Lys-Glu; modulates T-cell and NK cell activity; reduces age-related immune decline; normalizes cytokine production via epigenetic gene regulation

Vilon is a synthetic dipeptide (Lys-Glu, KE) classified as a Khavinson-class bioregulator originally derived from thymic tissue, proposed to modulate immune function in aging subjects by providing minimal thymic regulatory dipeptide signals that support T-lymphocyte activation and immune homeostasis diminished by age-related thymic involution. As the minimal active dipeptide unit of the Khavinson thymic bioregulator class, vilon is proposed to act through amino acid transporter uptake and modulation of intracellular signaling — including sphingomyelin pathway signal transduction in thymocytes — to restore T-cell activation thresholds and proliferative responses in immune cells from elderly subjects. Research has characterized natural and synthetic thymic peptides including vilon as therapeutic candidates for immune dysfunction, and experimental work has demonstrated that short Khavinson-class peptides modulate thymocyte blast transformation and sphingomyelin pathway signaling in immune cell preparations. Vilon has no FDA approval; evidence derives from Khavinson-series Russian preclinical and observational studies, and it has no regulatory approval in any major Western jurisdiction.

Vilon Benefits & Research Areas

immune modulationanti-agingimmune restorationLongevity

Research Signals

Population research notes

50+

These signals reflect research interest areas, not treatment indications.

Regulatory & Evidence

Risk Profile

Low Risk

Generally considered lower risk in research contexts. Risk profile varies by individual — review contraindications before use.

Regulatory Status

Availability Status
Research Only
FDA Status
Not Evaluated

Russian dipeptide bioregulator (Lys-Glu) from Khavinson Institute. Immunomodulatory and longevity research. Not FDA-approved. Not on any FDA list. Research chemical in US.

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Research Sources

2 sources cited · 2 moderate

1 Review · 1 Animal

  • Comparative study of the effects of vilon, epithalon, and cortagen on thymocyte proliferation and sphingomyelinase activity

    Bulletin of Experimental Biology and Medicine · 2002

    Research in mouse thymocyte cultures found that vilon produced the most potent comitogenic stimulation of thymocyte proliferation and sphingomyelinase activity compared with epithalon and cortagen, providing mechanistic evidence for its thymopoiesis-promoting activity and relevance to immune restoration in aging.

    AnimalModeratePMID 12420072
  • Immunomodulatory peptides from the thymus

    International Journal of Immunopharmacology · 1997

    This review describes the isolation of vilon (Lys-Glu) as the active immunomodulatory dipeptide from thymalin, documenting its activation of T-cell differentiation, cytokine regulatory activity, and comparison with thymogen, establishing it as the low-molecular-weight component responsible for thymalin's immune-modulating and geroprotective properties.

    ReviewModeratePMID 9637345

Vilon Side Effects & Safety Considerations

Low Risk

Generally considered lower risk in research contexts. Individual response varies — review all considerations before use.

Reported contraindications & considerations

None Established

Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.

Where to Buy Vilon — Providers & Availability

2 providers
2 in stock

Stay updated on verified Vilon providers

New verified providers added weekly — delivered to your inbox.

Weekly research digest. No spam. Unsubscribe anytime.

Questions to Ask Your Provider

Frequently Asked Questions — Vilon

Vilon is a synthetic dipeptide (Lys-Glu, KE) classified as a Khavinson-class bioregulator originally derived from thymic tissue, proposed to modulate immune function in aging subjects by providing minimal thymic regulatory dipeptide signals that support T-lymphocyte activation and immune homeostasis diminished by age-related thymic involution. As the minimal active dipeptide unit of the Khavinson thymic bioregulator class, vilon is proposed to act through amino acid transporter uptake and modulation of intracellular signaling — including sphingomyelin pathway signal transduction in thymocytes — to restore T-cell activation thresholds and proliferative responses in immune cells from elderly subjects.

immune modulation, anti-aging, immune restoration, Longevity.

Research on Vilon primarily documents effects related to immune modulation and anti-aging and immune restoration and Longevity. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.

Reported contraindications and considerations for Vilon include none established. This is educational information only — consult a qualified healthcare professional before use.

2 providers in the directory currently offer Vilon.

Research in mouse thymocyte cultures found that vilon produced the most potent comitogenic stimulation of thymocyte proliferation and sphingomyelinase activity compared with epithalon and cortagen, providing mechanistic evidence for its thymopoiesis-promoting activity and relevance to immune restoration in aging.

Last updated

Free newsletter

The Peptide Research Digest

Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.

No spam. Unsubscribe anytime. Privacy policy.

Free Guide

The Peptide Research Digest

Get our free provider vetting guide — plus weekly research briefings on peptide sourcing, COA verification, and clinical developments.

No spam.